BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27336872)

  • 1. Treatment and survival patterns of Chinese patients diagnosed with breast cancer between 2005 and 2009 in Southwest China: An observational, population-based cohort study.
    Peng Z; Wei J; Lu X; Zheng H; Zhong X; Gao W; Chen Y; Jing J
    Medicine (Baltimore); 2016 Jun; 95(25):e3865. PubMed ID: 27336872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
    Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
    Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
    Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
    Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China.
    Ye J; Wang W; Xin L; Owen S; Xu L; Duan X; Cheng Y; Zhang H; Zhang S; Li T; Liu Y
    Anticancer Res; 2017 Aug; 37(8):4549-4556. PubMed ID: 28739751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
    Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
    PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
    Conte B; Bruzzone M; Lambertini M; Poggio F; Bighin C; Blondeaux E; De Laurentiis M; Valle E; Cognetti F; Nisticò C; De Placido S; Garrone O; Gamucci T; Montemurro F; Puglisi F; Cardinali B; Fregatti P; Miglietta L; Boccardo F; Ceppi M; Del Mastro L;
    Eur J Cancer; 2020 Sep; 136():43-51. PubMed ID: 32634760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumor and 1-3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases.
    Shen H; Zhao L; Wang L; Liu X; Liu X; Liu J; Niu F; Lv S; Niu Y
    Tumour Biol; 2016 May; 37(5):6465-75. PubMed ID: 26631044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome in young women with breast cancer: a population-based study.
    Fredholm H; Magnusson K; Lindström LS; Garmo H; Fält SE; Lindman H; Bergh J; Holmberg L; Pontén F; Frisell J; Fredriksson I
    Breast Cancer Res Treat; 2016 Nov; 160(1):131-143. PubMed ID: 27624330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study.
    Zuo T; Zeng H; Li H; Liu S; Yang L; Xia C; Zheng R; Ma F; Liu L; Wang N; Xuan L; Chen W
    Chin J Cancer; 2017 Oct; 36(1):84. PubMed ID: 29070080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.